Clay Siegall received his doctorate in Genetics from George Washington University and a Bachelor of Science degree in Zoology from the University of Maryland. Clay Siegall co-founded Seattle Genetics in 1998 and currently serves as the company’s President, Chief Executive Officer, and Chairman of the Board of Directors. During the company’s establishment, cancer treatments were controlled by chemotherapy that could barely distinguish between killing cancer cells and normal cells. Clay wanted to improve the lives of people living with cancer through the development of targeted therapies to cater for unmet needs.
Clay Sieagall established Seattle Genetics on a scientific innovation basis along with meticulous research, drug development practice, and his zeal to assist others. Under his leadership, the company, Seattle Genetics, was able to build a diverse pipeline of antibody cancer therapies which include ADCETRIS (brentuximab vedotin) for cancer treatment. ADCETRIS is currently an international brand approved in over 65 nations.
Clay Siegall is also in charge of the Seattle Genetics capital-raising activities having secured over $675 million through private and public funding, in addition to the company’s first public offering in 2001. Clay Siegall previously served at the Bristol-Myers Squibb Pharmaceutical Research Institute for a six year period and prior to that, he worked with the National Cancer Institute, National Institutes of Health from 1988 to 1991. Clay is also a member of the Board of Directors of a private biotechnology firm-Alder Biopharmaceuticals. Clay Siegall is an author and has published over 70 books and also holds 15 patents.
Clay Siegall has led Seattle Genetics into multiple strategic licenses for the company’s ADC technology which include AbbVie, Genentech (Roche), Astellas, Pfizer, and GlaxoSmithKline which have collectively generated more than $350 million to this day. There are more than 20 ADCs in the clinical development that utilize the company’s technology across internal and partner programs. Clay says that an important component their business plan involves partnering with other industry leaders and innovators in oncology drug development. He adds that the company’s ADC collaborations have helped market their technology, allowing the company to place resources into new ideas and new approaches to help patients.